1. Phylogeny  
   Phosphatidylinositol 5‐phosphate 4‐kinase type‐2 beta (PIP4K2B) is a member of the phosphoinositide kinase family that is conserved throughout metazoans. Comparative analyses of the kinase domain indicate that PIP4K2B belongs to the type II PIP4K subgroup, which is distinct from the type I phosphatidylinositol 4‐kinases that primarily phosphorylate PI4P. In vertebrates, the PIP4K family is represented by multiple isoforms, most commonly PIP4K2A, PIP4K2B, and PIP4K2C; each isoform displays differences in catalytic activity, subcellular distribution, and regulatory mechanisms. Molecular phylogenetic studies have demonstrated that these isoforms resulted from ancestral gene duplication events in early metazoans, and they are characterized by highly conserved catalytic cores with divergence in their regulatory regions. Analysis of conserved signature indels (CSIs) within the kinase domain has revealed sequence markers that are unique to the PIP4K subfamilies, enabling the differentiation of PIP4K2B from its closely related isoforms. For instance, PIP4K2B exhibits specific insertions and deletions that are not present in the α and γ isoforms, thus supporting its classification as a discrete evolutionary branch within the PIP4K group (jin2023lipidkinasespip5ks pages 9-10, khadka2019novelmolecularsignatures pages 15-17). In addition, studies comparing the occurrence of PIP4K genes across eukaryotic species indicate that while simpler organisms such as yeast may lack these kinases, multicellular organisms have evolved multiple isoforms in order to fine-tune phosphoinositide signaling across different tissues and subcellular compartments. The evolutionary conservation of the central catalytic domain underscores the essential role of PIP4K2B in cellular signaling pathways, while variations in its regulatory domains are associated with isoform-specific functions observed in various mammals (doughman2003phosphatidylinositolphosphatekinases pages 3-4, khadka2019novelmolecularsignatures pages 1-3). Thus, the phylogenetic context of PIP4K2B reflects both its deep evolutionary roots in the core phosphoinositide kinase network and its divergence into specialized roles that support tissue‐ and context‐specific signaling functions (jin2023lipidkinasespip5ks pages 1-2, khadka2019novelmolecularsignatures pages 3-4).
2. Reaction Catalyzed  
   PIP4K2B catalyzes the phosphorylation of phosphatidylinositol 5‐phosphate (PI5P) at the 4‐hydroxyl position of the inositol ring to generate phosphatidylinositol 4,5‐bisphosphate [PI(4,5)P2]. Under canonical kinase reaction conditions, this process follows the general mechanism in which a phosphate group is transferred from a nucleotide triphosphate to the substrate, resulting in the production of a corresponding diphosphate and a proton. In the case of PIP4K2B, although many protein and lipid kinases utilize ATP as a phosphate donor, this enzyme is unique in that it preferentially utilizes GTP—a property that links its activity directly to the physiological concentrations of GTP and thereby couples phosphoinositide metabolism to cellular energy status. Thus, the overall chemical reaction catalyzed by PIP4K2B can be represented as:  
     GTP + PI5P → GDP + PI(4,5)P2 + H⁺  
   This reaction is critical for ensuring the proper supply of PI(4,5)P2, a lipid second messenger that serves as a precursor for further downstream signaling molecules such as PI(3,4,5)P3, and for maintaining spatially defined pools of phosphoinositides that mediate numerous cellular processes (jin2023lipidkinasespip5ks pages 2-4, jin2023lipidkinasespip5ks pages 10-10, poli2019phosphatidylinositol5phosphate pages 7-9).
3. Cofactor Requirements  
   The catalytic activity of PIP4K2B is dependent on the presence of divalent metal ions, which are essential for stabilizing negative charges during the phosphotransfer reaction. Consistent with the biochemical requirements observed for many kinase enzymes, PIP4K2B requires magnesium ions (Mg²⁺) to facilitate the nucleotide-binding process and properly orient the phosphate donor within the catalytic site. Although the enzyme preferentially uses GTP as a substrate, the requirement for Mg²⁺ remains a constant feature in the catalytic mechanism, stabilizing the β- and γ-phosphates of the nucleotide and enabling efficient phosphate transfer to PI5P (doughman2003phosphatidylinositolphosphatekinases pages 1-3, tariq2021strikingabalance pages 15-17). This cofactor dependency ensures that enzyme kinetics are appropriately modulated by intracellular ion concentrations, integrating signals from both energy metabolism and ionic homeostasis (jin2023lipidkinasespip5ks pages 1-2).
4. Substrate Specificity  
   PIP4K2B is highly specific for phosphatidylinositol 5‐phosphate (PI5P) as its substrate. The enzyme’s structure has evolved to make precise contacts with PI5P, thereby ensuring that the phosphorylation reaction occurs specifically at the 4-position of the inositol ring and results in the production of PI(4,5)P2. Unlike protein kinases that typically recognize specific amino acid motifs, the substrate specificity of PIP4K2B is determined by the recognition of the lipid headgroup structure of PI5P. Detailed biochemical studies have demonstrated that the catalytic domain of PIP4K2B includes residues that provide high-affinity binding to PI5P, and these interactions facilitate the precise transfer of a phosphate group to the target hydroxyl group (poli2019phosphatidylinositol5phosphate pages 7-9, jin2023lipidkinasespip5ks pages 1-2). Additionally, mutagenesis experiments have corroborated the importance of these residues in determining activity; substitutions within key binding regions result in a marked decrease in catalytic efficiency, which highlights the high degree of substrate specificity inherent to this enzyme (doughman2003phosphatidylinositolphosphatekinases pages 3-4, khadka2019novelmolecularsignatures pages 12-15). Therefore, the substrate specificity of PIP4K2B is defined chiefly by its ability to selectively bind and modify PI5P, an essential step for the regulated synthesis of PI(4,5)P2 in various cellular contexts (jin2023lipidkinasespip5ks pages 1-2).
5. Structure  
   The three-dimensional structure of PIP4K2B is characterized by a canonical protein kinase-like fold that is shared with other members of the phosphoinositide kinase family. Its overall architecture comprises a small N-terminal lobe, mostly formed by β-strands, and a larger C-terminal lobe dominated by α-helices. This bilobal kinase core forms a cleft that accommodates both the nucleotide substrate and the lipid substrate, enabling the enzyme to catalyze the transfer of a phosphate group with high specificity (doughman2003phosphatidylinositolphosphatekinases pages 3-4, jin2023lipidkinasespip5ks pages 4-5). Within the catalytic core, the activation loop plays a critical role in substrate recognition and catalysis. Notably, a conserved alanine residue within this loop (for example, A381 in human PIP4K2B, as identified in mutational analyses) is essential for defining the substrate specificity toward PI5P and ensuring the correct orientation of the inositol ring during the reaction (doughman2003phosphatidylinositolphosphatekinases pages 3-4, khadka2019novelmolecularsignatures pages 12-15). In addition to the catalytic domain, comparative sequence analyses reveal that PIP4K2B contains isoform-specific regions in its N- and C-terminal extensions that likely contribute to differential subcellular localization and regulation. Studies using homology modeling and crystallographic data from related PIP kinases have provided insights into the unique structural features of PIP4K2B, including distinct surface-exposed loops that may serve as platforms for interacting with regulatory proteins or lipid membranes (jin2023lipidkinasespip5ks pages 9-9, khadka2019novelmolecularsignatures pages 15-17). These structural elements, together with the central kinase domain, enable PIP4K2B to integrate nucleotide sensing (by virtue of its GTP preference) with precise lipid substrate engagement. The proper alignment of key structural motifs—such as the catalytic loop, the DFG motif, and the C-helix—is essential for maintaining the enzyme’s activity and ensuring efficient phosphorylation of the lipid substrate (doughman2003phosphatidylinositolphosphatekinases pages 4-6, khadka2019novelmolecularsignatures pages 15-17). Overall, the domain organization and three-dimensional architecture of PIP4K2B underscore the structural basis for its unique catalytic and regulatory properties.
6. Regulation  
   Regulation of PIP4K2B is achieved through a combination of post-translational modifications and specific protein–protein interactions that fine-tune its enzymatic activity and subcellular localization. A major regulatory mechanism involves phosphorylation events; for instance, p38 mitogen-activated protein kinase (MAPK) has been shown to phosphorylate PIP4K2B on serine 326, an event that results in the inhibition of its lipid kinase activity. This phosphorylation is part of a stress-response pathway and serves to modulate the cellular levels of PI5P and PI(4,5)P2 under conditions such as oxidative stress or UV irradiation (jin2023lipidkinasespip5ks pages 5-6, poli2019phosphatidylinositol5phosphate pages 5-7). In addition to direct phosphorylation, regulatory control is exerted via interactions with the peptidyl-prolyl isomerase Pin1. PIP4K2B contains phosphorylated sites, including Thr322 and Ser326, which facilitate binding to Pin1; this interaction is instrumental in modulating the enzyme’s conformational state and decreasing its catalytic efficiency, thereby influencing nuclear PI5P levels (poli2019phosphatidylinositol5phosphate pages 7-9, jin2023lipidkinasespip5ks pages 5-6). Moreover, PIP4K2B can be regulated by ubiquitin-mediated degradation; interactions with ubiquitin ligase complexes, such as the Cul3-SPOP complex, have been implicated in targeting the enzyme for ubiquitination and subsequent proteasomal turnover, thus affecting its steady-state levels within the cell (jin2023lipidkinasespip5ks pages 5-6, khadka2019novelmolecularsignatures pages 20-21). These regulatory mechanisms ensure that PIP4K2B activity is tightly controlled in response to cellular stress, nutrient availability, and changes in energy status. Additionally, although not as extensively characterized as the phosphorylation-dependent regulation, there is evidence that small GTPases and other signaling factors may influence the membrane recruitment and conformational dynamics of PIP4K2B, thereby modulating its activity under specific physiological conditions (tariq2021strikingabalance pages 17-18). Collectively, these post-translational modifications and interaction networks integrate environmental and intracellular signals, allowing PIP4K2B to serve as an effective mediator of phosphoinositide metabolism and cellular lipid signaling.
7. Function  
   PIP4K2B plays a central role in maintaining the cellular balance of phosphoinositides by catalyzing the conversion of PI5P to PI(4,5)P2. This enzymatic activity has broad implications for cell signaling, membrane dynamics, and metabolic regulation. The production of PI(4,5)P2 by PIP4K2B is essential for downstream signaling events, including the activation of PI3K, which converts PI(4,5)P2 to PI(3,4,5)P3—an important step in propagating signals linked to cell growth and survival (jin2023lipidkinasespip5ks pages 1-2, poli2019phosphatidylinositol5phosphate pages 7-9). In addition to its catalytic role in phosphoinositide synthesis, PIP4K2B is distinguished by its unique GTP-sensing capability; its preferential utilization of GTP rather than ATP allows the enzyme’s activity to directly reflect physiological GTP concentrations, thereby coupling cellular energy status with lipid signaling. This GTP‐sensing mechanism is a critical factor in metabolic adaptation, ensuring that cellular responses to fluctuations in energy and nutrient levels are properly coordinated (jin2023lipidkinasespip5ks pages 6-7, tariq2021strikingabalance pages 1-3). Furthermore, PIP4K2B exerts regulatory influences on insulin signaling pathways. It has been shown to interact with PIP5K isoforms, and through a catalytic-independent mechanism, it suppresses PIP5K‐mediated synthesis of PI(4,5)P2 and the subsequent conversion to PI(3,4,5)P3, thereby exerting a negative regulatory effect on insulin-dependent pathways (jin2023lipidkinasespip5ks pages 5-6, OpenTargets Search: -PIP4K2B). This interaction is of particular relevance given the critical role of phosphoinositides in modulating both metabolic homeostasis and cell growth. Additionally, PIP4K2B has been implicated in the regulation of nuclear signaling. Alterations in PIP4K2B activity affect nuclear PI5P pools, which in turn modulate the function of nuclear proteins such as ING2. The recruitment of ING2 by elevated levels of PI5P has been linked to enhanced p53 acetylation and the modulation of apoptotic pathways, thus connecting PIP4K2B to mechanisms of cell stress response and tumor suppression (poli2019phosphatidylinositol5phosphate pages 5-7). In the context of cancer biology, particularly in breast cancer, differential expression of PIP4K2B has been observed. Both increased and decreased levels of PIP4K2B have been correlated with alterations in cell proliferation, anchorage-independent growth, and overall patient survival, with its expression frequently associated with co-amplification of oncogenic drivers such as ERBB2 and disruptions in p53 signaling (jin2023lipidkinasespip5ks pages 5-6, jin2023lipidkinasespip5ks pages 9-10). Therefore, PIP4K2B functions as an integral component of the signaling networks that govern metabolic adaptation, insulin signaling, and stress responses, rendering it a critical regulator of cellular homeostasis.
8. Other Comments  
   In addition to its well‐characterized catalytic and regulatory roles, PIP4K2B has emerged as a promising therapeutic target in several disease contexts. Researchers have identified a range of small-molecule inhibitors that specifically target PIP4K isoforms, with SAR088 being noted as the first orally available and in vivo active inhibitor selective for PIP4K2B. Other compounds such as THZ-P1-2, BAY-091, and I-Ome Tyrphostin AG-538 have been reported to exhibit varying degrees of selectivity and potency toward PIP4K isoforms, offering potential avenues for pharmacological intervention in conditions where aberrant phosphoinositide signaling plays a pathogenic role (jin2023lipidkinasespip5ks pages 5-6, jin2023lipidkinasespip5ks pages 7-8). Dysregulation of PIP4K2B is strongly associated with breast cancer, where its altered expression—either as an overexpressed or underexpressed isoform—correlates with changes in cell proliferation and tumorigenic growth. Its interaction with major oncogenic and tumor suppressor pathways, including those mediated by ERBB2 and p53, underlines its clinical significance in oncology. Moreover, due to its role in the negative regulation of insulin signaling via interactions with PIP5Ks, PIP4K2B is also implicated in metabolic disorders such as type 2 diabetes and obesity. The enzyme’s GTP-sensing capability further ties its activity to the metabolic state of the cell, providing a molecular link between energy homeostasis and lipid signaling. These additional functional attributes, combined with its distinct regulatory mechanisms, have stimulated significant interest in developing PIP4K2B inhibitors as targeted therapeutics. Although the full spectrum of its disease associations continues to be elucidated, current evidence supports a multifaceted role for PIP4K2B in metabolic regulation, cancer progression, and stress response, which reinforces its potential as an attractive target for drug development (jin2023lipidkinasespip5ks pages 8-9, jin2023lipidkinasespip5ks pages 9-9, tariq2021strikingabalance pages 15-17).
9. References
10. Jin, Y. and Xue, J. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023, doi:10.3389/fonc.2023.1323897
11. Poli, A., Zaurito, A., Abdul-Hamid, S., Fiume, R., Faenza, I., and Divecha, N. Phosphatidylinositol 5 phosphate (pi5p): from behind the scenes to the front (nuclear) stage. International Journal of Molecular Sciences, Apr 2019, doi:10.3390/ijms20092080
12. Doughman, R. L., Firestone, A. J., and Anderson, R. Phosphatidylinositol phosphate kinases put pi4,5p2 in its place. The Journal of Membrane Biology, Jul 2003, doi:10.1007/s00232-003-2027-7
13. Khadka, B. and Gupta, R. S. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019, doi:10.3390/genes10040312
14. Tariq, K. and Luikart, B. W. Striking a balance: pip2 and pip3 signaling in neuronal health and disease. Exploration of neuroprotective therapy, Oct 2021, doi:10.37349/ent.2021.00008
15. Wang, Y.-H. and Sheetz, M. P. When pip2 meets p53: nuclear phosphoinositide signaling in the dna damage response. Frontiers in Cell and Developmental Biology, May 2022, doi:10.3389/fcell.2022.903994

References

1. (jin2023lipidkinasespip5ks pages 6-7): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
2. (jin2023lipidkinasespip5ks pages 7-8): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
3. (poli2019phosphatidylinositol5phosphate pages 7-9): A. Poli, A. Zaurito, Shidqiyyah Abdul-Hamid, R. Fiume, I. Faenza, and N. Divecha. Phosphatidylinositol 5 phosphate (pi5p): from behind the scenes to the front (nuclear) stage. International Journal of Molecular Sciences, Apr 2019. URL: https://doi.org/10.3390/ijms20092080, doi:10.3390/ijms20092080. This article has 46 citations and is from a peer-reviewed journal.
4. (OpenTargets Search: -PIP4K2B): Open Targets Query (-PIP4K2B, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
5. (doughman2003phosphatidylinositolphosphatekinases pages 1-3): Renee L. Doughman, Ari J. Firestone, and R. Anderson. Phosphatidylinositol phosphate kinases put pi4,5p2 in its place. The Journal of Membrane Biology, 194:77-89, Jul 2003. URL: https://doi.org/10.1007/s00232-003-2027-7, doi:10.1007/s00232-003-2027-7. This article has 334 citations.
6. (doughman2003phosphatidylinositolphosphatekinases pages 3-4): Renee L. Doughman, Ari J. Firestone, and R. Anderson. Phosphatidylinositol phosphate kinases put pi4,5p2 in its place. The Journal of Membrane Biology, 194:77-89, Jul 2003. URL: https://doi.org/10.1007/s00232-003-2027-7, doi:10.1007/s00232-003-2027-7. This article has 334 citations.
7. (jin2023lipidkinasespip5ks pages 1-2): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
8. (jin2023lipidkinasespip5ks pages 10-10): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
9. (jin2023lipidkinasespip5ks pages 2-4): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
10. (jin2023lipidkinasespip5ks pages 4-5): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
11. (jin2023lipidkinasespip5ks pages 5-6): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
12. (jin2023lipidkinasespip5ks pages 8-9): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
13. (jin2023lipidkinasespip5ks pages 9-10): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
14. (jin2023lipidkinasespip5ks pages 9-9): Yue Jin and Jian Xue. Lipid kinases pip5ks and pip4ks: potential drug targets for breast cancer. Frontiers in Oncology, Dec 2023. URL: https://doi.org/10.3389/fonc.2023.1323897, doi:10.3389/fonc.2023.1323897. This article has 2 citations and is from a peer-reviewed journal.
15. (khadka2019novelmolecularsignatures pages 1-3): Bijendra Khadka and Radhey S. Gupta. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019. URL: https://doi.org/10.3390/genes10040312, doi:10.3390/genes10040312. This article has 14 citations and is from a peer-reviewed journal.
16. (khadka2019novelmolecularsignatures pages 20-21): Bijendra Khadka and Radhey S. Gupta. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019. URL: https://doi.org/10.3390/genes10040312, doi:10.3390/genes10040312. This article has 14 citations and is from a peer-reviewed journal.
17. (tariq2021strikingabalance pages 1-3): K. Tariq and Bryan W. Luikart. Striking a balance: pip2 and pip3 signaling in neuronal health and disease. Exploration of neuroprotective therapy, 1:86-100, Oct 2021. URL: https://doi.org/10.37349/ent.2021.00008, doi:10.37349/ent.2021.00008. This article has 47 citations.
18. (tariq2021strikingabalance pages 17-18): K. Tariq and Bryan W. Luikart. Striking a balance: pip2 and pip3 signaling in neuronal health and disease. Exploration of neuroprotective therapy, 1:86-100, Oct 2021. URL: https://doi.org/10.37349/ent.2021.00008, doi:10.37349/ent.2021.00008. This article has 47 citations.
19. (doughman2003phosphatidylinositolphosphatekinases pages 4-6): Renee L. Doughman, Ari J. Firestone, and R. Anderson. Phosphatidylinositol phosphate kinases put pi4,5p2 in its place. The Journal of Membrane Biology, 194:77-89, Jul 2003. URL: https://doi.org/10.1007/s00232-003-2027-7, doi:10.1007/s00232-003-2027-7. This article has 334 citations.
20. (khadka2019novelmolecularsignatures pages 12-15): Bijendra Khadka and Radhey S. Gupta. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019. URL: https://doi.org/10.3390/genes10040312, doi:10.3390/genes10040312. This article has 14 citations and is from a peer-reviewed journal.
21. (khadka2019novelmolecularsignatures pages 15-17): Bijendra Khadka and Radhey S. Gupta. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019. URL: https://doi.org/10.3390/genes10040312, doi:10.3390/genes10040312. This article has 14 citations and is from a peer-reviewed journal.
22. (khadka2019novelmolecularsignatures pages 3-4): Bijendra Khadka and Radhey S. Gupta. Novel molecular signatures in the pip4k/pip5k family of proteins specific for different isozymes and subfamilies provide important insights into the evolutionary divergence of this protein family. Genes, Apr 2019. URL: https://doi.org/10.3390/genes10040312, doi:10.3390/genes10040312. This article has 14 citations and is from a peer-reviewed journal.
23. (poli2019phosphatidylinositol5phosphate pages 5-7): A. Poli, A. Zaurito, Shidqiyyah Abdul-Hamid, R. Fiume, I. Faenza, and N. Divecha. Phosphatidylinositol 5 phosphate (pi5p): from behind the scenes to the front (nuclear) stage. International Journal of Molecular Sciences, Apr 2019. URL: https://doi.org/10.3390/ijms20092080, doi:10.3390/ijms20092080. This article has 46 citations and is from a peer-reviewed journal.
24. (tariq2021strikingabalance pages 15-17): K. Tariq and Bryan W. Luikart. Striking a balance: pip2 and pip3 signaling in neuronal health and disease. Exploration of neuroprotective therapy, 1:86-100, Oct 2021. URL: https://doi.org/10.37349/ent.2021.00008, doi:10.37349/ent.2021.00008. This article has 47 citations.